Pancreatic Cancer Precision Medicine Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 690.11 Mn

Forecast Year, 2034

USD 4,030.16 Mn

CAGR, 2025 - 2034

19.30%

Report Coverage

Global

What is Pancreatic Cancer Precision Medicine Market Size?

The global pancreatic cancer precision medicine market size accounted for USD 823.30 million in 2025 and is predicted to increase from USD 982.20 million in 2026 to approximately USD 4,030.16 million by 2034, expanding at a CAGR of 19.30% from 2025 to 2034. The growing adoption of targeted therapies is the key factor driving the growth of the market. Also, the increasing shift towards precision medicine, coupled with the ongoing integration of bioinformatics and next-generation sequencing technologies, can fuel market growth further.

Market Highlights

• North America held the largest market share of 43% in 2024.
• Asia Pacific is expected to grow at the fastest CAGR of 7% during the forecast period.
• By therapeutic approach, the targeted therapy segment contributed the highest market share of 57% in 2024.
• By therapeutic approach, the chemotherapy precision combination segment is expected to grow at the fastest CAGR of 21% over the forecast period.
• By diagnostic technology, the genomic testing segment accounted for the biggest market share of 41% in 2024.
• By diagnostic technology, the liquid biopsy segment is projected to grow at a CAGR of 21% during the forecast period.

Market Overview

The pancreatic cancer precision medicine market emphasizes specific treatment plans to individuals' unique properties, rather than utilizing a one-size-fits-all approach. This attitude aims to enhance treatment efficacy and reduce the side effects by tailoring therapies to the key characteristics of each patient's pancreatic cancer. The treatment uses molecular diagnostics and genomic profiling to detect some genetic alterations that cause pancreatic cancer and guide treatment decisions.

Role of AI in Improving Pancreatic Disease Diagnosis

Artificial Intelligence plays a transformative role in the pancreatic cancer precision medicine market by improving timely detection, diagnosis, and treatment selection systems by analyzing patient data, medical images, and genomic information to find high-risk groups, tailor treatment plans, and predict survival duration, which can lead to enhanced patient outcomes. Furthermore, AI can help in the progression of computer-assisted diagnostic systems, enhancing overall efficiency and accuracy can also optimise the design and development of newly launched drugs for pancreatic cancer.

• In December 2024, Paris-based Orakl Oncology raised € 11 million to launch AI-powered drug development tools. The funds will be used to accelerate the commercial launch of its AI-powered solutions, O-Predict and O-Validate, and to strengthen strategic collaborations with pharmaceutical partners.

Pancreatic Cancer Precision Medicine Market Growth Factors

• The growing investment in research and development is expected to boost the pancreatic cancer precision medicine market growth soon.
• The rapid development of immunotherapies and targeted therapies can propel market growth shortly.
• Regulatory support and government funding will likely contribute to the market expansion during the forecast period.

Market Outlook

• Industry Growth Overview: The pancreatic cancer precision medicine market is expanding steadily, fueled by advances in genomic profiling, targeted therapies, and biomarker-driven diaganostics. Collaborations among biotech, diagnostics companies, and academic institutions, along with regulatory support and increased patient stratification, are driving the development of personalized treatments and better outcomes.
• Global Expansion:The market is growing worldwide with increased adoption of molecular diagnostics, expanding clinical trials across North America, Europe, and Asia Pacific, higher healthcare investments, broader access to advanced sequencing technologies, and stronger collaborations between research institutes, pharmaceutical companies, and oncology centers.
• Major investors: Major investors in the market include biotechnology firms, pharmaceutical companies, venture capital groups, and government research agencies funding targeted therapeutics, genomic research, and biomarker development. Strategic funding rounds, clinical trial support, and public-private partnerships are accelerating innovation, drug discovery, and commercialization of personalized treatment solutions.
• Startup Ecosystem: The market's startup ecosystem is gaining momentum, with emerging biotech firms focusing on genomic sequencing, liquid biopsy tools, AI-based diagnostics, and targeted drug development. Support from accelerators, venture capital, and research collaborations is fostering innovation and speeding clinical translation of personalized therapies for patients.

Market Scope

Market Dynamics

Drivers

Ongoing development of innovative therapies

Lifestyle-related factors and the aging population are the major causes of the increase in pancreatic cancer cases. Innovations in medical technology, including nanotechnology and targeted therapies, provide promising potential. In addition, the surge in government initiatives and increasing awareness about disease treatments propel the investment in research and development of new drugs. Academic institutions and pharmaceutical companies are actively conducting research and development activities.In

• January 2023, Personalized therapy simulation company Cellworks announced the launch of two separate business units that will take an in-silico approach to testing potential new precision oncology drugs in both pre-clinical and clinical stages. The new business units will employ Cellworks' biosimulation and computational bio-simulation model (CBM) to streamline clinical trials.

Restraint

Lack of qualified specialist

The shortage of qualified specialists is the major factor hindering the pancreatic cancer precision medicine market growth. The high treatment costs and limited healthcare infrastructure in developing nations are also negatively affecting market expansion. However, a lack of public awareness and stringent regulatory guidelines can restrict market expansion. The disease also remains asymptomatic in the first stages, which makes it challenging to detect and delay treatment further.

Opportunity

Strong presence of pipeline products

Shifting the focus of major players in R&D activities to launch new drugs and a surge in funding for cancer treatment and research can lead to the development of innovative drugs and treatments in the pancreatic cancer precision medicine market. Furthermore, many pharmaceutical companies are engaged in clinical trials to explore the effect and potential of the molecule for disease treatment. Also, researchers and scientists from various research institutes are emphasizing more towards the development of individualized medicines for pancreatic cancer treatment.

According to the October 2024, Gov.UK, press release, NHS cancer patients are benefitting from partnerships with pharmaceutical companies and universities to spot cancer sooner through trials for new technologies, such as AI. Innovations have the potential to transform treatment for NHS patients and launch a wave of globally significant new Medtech products.

Segment Insights

Therapeutic Approach Insights

The targeted therapy segment dominated the pancreatic cancer precision medicine market in 2024. The dominance of the segment can be attributed to the innovation in genomic profiling and individualized treatment. These therapy options provide benefits such as fewer side effects, less harm to healthy cells, and enhanced effectiveness compared to conventional chemotherapy. Additionally, targeted therapies can be specific to genetic characteristics or mutations found in a patient's tumor, enabling more effective and personalized treatment.

• In August 2024, Servier's VORANIGO (vorasidenib) tablets received FDA approval as the first targeted therapy for Grade 2 IDH-mutant Glioma.VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.

The chemotherapy precision combination segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be credited to the increasing shift towards integrating chemotherapy with precision medicine. Chemotherapy precision can lead to better rates of tumor response and longer survival times for some patients, especially those with specific genetic mutations. Also, regulatory support can optimize the development and approval of these advanced therapies, impacting positive segment growth soon.

Diagnostic Technology Insights

The genomic testing segment held the largest pancreatic cancer precision medicine market share in 2024. The dominance of the segment can be linked to the raised funding and regulatory support for genomic testing, coupled with advanced genomic testing technologies. Moreover, genomic testing can reveal inherited mutations, particularly guiding treatment choices and informing other members of the family regarding the risk of developing cancer. Genomic studies facilitate a deeper understanding of pancreatic cancer.

The liquid biopsy segment is projected to grow at the fastest rate during the forecast period. The growth of the segment can be driven by the benefits offered by liquid biopsies, such as early detection and timely monitoring. Unlike conventional biopsies, liquid biopsies are less invasive and enable more rapid sampling, offering a dynamic view of tumor properties and treatment response. Furthermore, liquid biopsies can offer information regarding potential mutations, drug resistance, and other factors, helping in planning customized treatment strategies.

• In September 2024, Strand Life Sciences, a subsidiary of Reliance Industries Limited, announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test. According to the company's statement, this test detects circulating tumor DNA in blood samples of cancer patients to provide a comprehensive analysis of 74 clinically relevant genes, providing invaluable insights for cancer treatment.

Regional Insights

U.S. Pancreatic Cancer Precision Medicine Market Size and Growth 2025 to 2034

The U.S. pancreatic cancer precision medicine market size is exhibited at USD 290.30 million in 2025 and is projected to be worth around USD 1446.32 million by 2034, growing at a CAGR of 19.51% from 2025 to 2034.

North America held the largest pancreatic cancer precision medicine market share in 2024. The dominance of the region can be attributed to the ongoing research and development initiatives in targeted therapies and genetic profiling, along with advanced precision medicine treatments. Moreover, favorable government policies and the surge in the introduction of awareness programs by the government will likely contribute to regional growth soon.

U.S. Market Trends

In North America, the U.S. led the market in 2024, owing to the surge in pancreatic cancer cases in the region, and innovations in liquid biopsies & genomic testing enhance treatment personalization and early disease detection. Also, the raised awareness regarding precision medicine among the majority of players in the region is expanding the country's growth soon.

• In July 2024, Researchers from the American Cancer Society and International Agency for Research on Cancer estimated that 40% of all cancer cases in the United States in people 30 and up were due to "potentially modifiable risk factors," including cigarette smoking, physical inactivity, consumption of processed meat, viruses, excess body weight, alcohol drinking and more.

What Makes Asia Pacific the Fastest-Growing Region in the Market?

Asia Pacific is expected to grow at the fastest rate in the pancreatic cancer precision medicine market. The growth of the region can be credited to the surge in pancreatic cancer cases, along with the innovations in healthcare infrastructure and diagnostic settings. Furthermore, the strong presence of well-established critical care centers and hospitals with a huge population suffering from pancreatic cancer is propelling market growth in the region.

China Market Trends

In Asia Pacific, China dominated the pancreatic cancer precision medicine market. The dominance of the country can be driven by an enhancement in healthcare infrastructure and a surge in the number of pharmaceutical market players in the country. Significant investments in cancer research have facilitated the innovation of precision therapies specific to individuals' needs

How Big is the Opportunity for Market Growth in Europe?

Europe presents significant opportunities for the growth of the pancreatic cancer precision medicine market due to expanding genomic research programs, increased adoption of companion diagnostics, and high investment in clinical trials. Germany leads the market in Europe. This is primarily due to Supportive regulatory frameworks, a strong healthcare infrastructure, and collaborations between academic institutes and pharmaceutical companies, which are speeding up personalized treatment development and enhancing patient access to advanced therapies.

How Crucial is the Role of Latin America in the Pancreatic Cancer Precision Medicine Market?

Latin America is emerging as a major player in the market due to increasing investments in cancer research, greater access to molecular diagnostic tools, and improved healthcare systems. Increased clinical trial participation, government initiatives to improve cancer treatment, and collaborations with global pharmaceutical and biotech companies are further driving the adoption of personalized therapies in the region.

Brazil dominates the Latin America pancreatic cancer precision medicine market due to its strong oncology research ecosystem, early adoption of genomic sequencing technologies, and expanding network of specialized cancer centers. Rising government and private investment in precision diagnostics, increased clinical trial activity, and collaborations with global pharmaceutical and biotech companies further enhance its leadership role in the region.

What Potentiates the Growth of the Middle East and Africa Pancreatic Cancer Precision Medicine Market?

The market in the Middle East and Africa is fueled by increasing awareness of personalized oncology, expanding diagnostic infrastructure, and rising investment in advanced genomic technologies. Growing collaboration with international research organizations, government efforts to upgrade cancer treatment facilities, and increasing private healthcare spending are supporting broader adoption of precision-based therapeutic approaches in the region.

The UAE dominates the market in the Middle East and Africa due to its advanced healthcare infrastructure, rapid adoption of genomic sequencing and biomarker-based diagnostics, and strong government focus on precision oncology. High investment in cancer research centers, clinical trials, and international collaborations further strengthens its leadership in the region.

Value Chain Analysis

• Research and Development
  This stage involves identifying genomic biomarkers, developing targeted drug candidates, and designing precision diagnostics through molecular profiling and translational research.
  Key Players: Roche, Novartis, Pfizer, AstraZeneca, Foundation Medicine, Guardant Health, Thermo Fisher Scientific, Illumina.
• Clinical Trials and Regulatory Approval
  Conducting multi-phase clinical trials to evaluate the safety and efficacy of precision therapies, followed by regulatory submissions and approval for commercial use.
  Key Players: National Cancer Institute (NCI), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), MD Anderson Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center.
• Patient Support and Services
  Delivering precision treatment plans, genomic counseling, therapy monitoring, and reimbursement assistance to improve access and patient outcomes.
  Key Players: Oncology specialty hospitals, genetic counseling centers, cancer care networks, insurance providers, and patient advocacy groups such as Pancreatic Cancer Action Network (PanCAN).

Key players in Pancreatic Cancer Precision Medicine Market and Their Offerings

• AstraZeneca:AstraZeneca focuses on precision therapeutics targeting DNA damage repair pathways, immuno-oncology, and genomic biomarkers. The company develops combination therapies and companion diagnostics to personalize pancreatic cancer treatment based on tumor-specific mutations.
• Pfizer Inc. :Pfizer advances targeted drug programs and immunotherapy platforms for pancreatic cancer, supported by biomarker-based clinical trials and genomic profiling. Its precision pipeline includes therapies designed to address mutation-driven tumor progression and therapy resistance.
• Novartis AG:Novartis AG emphasizes molecularly targeted therapy development and adaptive clinical trial models for pancreatic cancer. It integrates genomic sequencing, predictive biomarkers, and real-world analytics to optimize individualized treatment selection and patient outcomes.
• Amgen, Inc.:Amgen develops precision medicines centered on KRAS-driven tumor biology, immuno-modulation, and protein engineering. The company's oncology pipeline includes therapies aimed at inhibiting specific oncogenic mutations frequently seen in pancreatic tumors.
• F. Hoffmann-La Roche Ltd. :Roche provides an integrated portfolio of companion diagnostics, genomic testing, and targeted anti-cancer medicines. Through its advanced sequencing platforms and oncology therapeutics, it enables precise molecular identification and personalized therapy planning for pancreatic cancer patients.
• Bayer AG:Bayer invests in targeted oncology therapeutics and precision radiology solutions for pancreatic cancer. Its R&D initiatives include pathway-specific inhibitors and biomarker-guided drug development to improve treatment efficacy and disease monitoring.
• Merck & Co., Inc.:Merck leads in precision immunotherapy for pancreatic cancer, developing checkpoint inhibitors and biomarker-stratified treatment regimens. The company expands clinical programs focused on tumor immunogenicity, genetic profiling, and combination precision strategies.
• Teva Pharmaceutical Industries Ltd:Teva contributes to the precision oncology landscape through supportive therapies, biosimilars, and drug delivery innovations that enhance accessibility to targeted pancreatic cancer treatments. Its focus includes improving treatment affordability and patient therapy management.
• Genentech, Inc.:Genentech pioneers molecularly targeted drugs and immunotherapy portfolios specifically guided by biomarker identification. It develops tumor genetic profiling, liquid biopsy-based monitoring, and precision-based drug combinations to improve survival in pancreatic cancer.
• Eli Lilly and Company:Eli Lilly contributes to the market through its development of targeted therapies and innovative immuno-oncology treatments, aiming to improve outcomes for patients with advanced pancreatic cancer.
• PharmaCyte Biotech, Inc.:PharmaCyte Biotech focuses on precision medicine for pancreatic cancer by advancing its novel Cell-in-a-Box technology, which delivers targeted chemotherapy directly to cancer cells, potentially improving treatment efficacy and reducing side effects.

Latest Announcement by Market Leaders

• In March 2025, AstraZeneca announced a USD 2.5 billion investment in a research and development hub in Beijing, underscoring its commitment to China, its second-largest market. This initiative includes two licensing deals with Chinese firms and aims to leverage Beijing's advanced life sciences and AI capabilities. Chief executive Pascal Soriot highlights the extensive collaboration opportunities and access to talent in China.
• In January 2025, Pfizer Inc. announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

Segments Covered in the Report

By Therapeutic Approach

• Targeted Therapy
• PARP Inhibitors
• Monoclonal Antibodies
• Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
• Immunotherapy
• Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
• Cancer Vaccines - GVAX, Algenpantucel-L
• Adoptive T-Cell Therapies - CAR-T therapies
• Chemotherapy-Precision Combinations
• Other Therapeutic Approaches

By Diagnostic Technology

• Genomic Testing
• Molecular Diagnostics
• Liquid Biopsy
• Biomarker-based Companion Diagnostics
• Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa